Discovery of a first-in-class inhibitor of the PRMT5-substrate adaptor interaction
McKinney, D. C.; McMillan, B. J.; Ranaghan, M.; Moroco, J. A.; Brousseau, M.; Mullin-Bernstein, Z.; O'Keefe, M.; McCarren, P.; Mesleh, M. F.; Mulvaney, K. M.; Singh, R.; Bajrami, B.; Skepner, A.; Timm, D. E.; Porter, D.; Kaushik, V.; Sellers, W. R.; Ianari, A.
Show abstract
PRMT5 and its substrate adaptor proteins (SAPs), pICln and Riok1, are synthetic lethal dependencies in MTAP-deleted cancer cells. SAPs share a conserved PRMT5 binding motif (PBM) which mediates binding to a surface of PRMT5 distal to the catalytic site. This interaction is required for methylation of several PRMT5 substrates, including histone and spliceosome complexes. We screened for small molecule inhibitors of the PRMT5-PBM interaction and validated a compound series which binds to the PRMT5-PBM interface and directly inhibits binding of SAPs. Mode of action and structure determination studies revealed that these compounds form a covalent bond between a halogenated pyridazinone group and cysteine 278 of PRMT5. Optimization of the starting hit produced a lead compound, BRD0639, which engages the target in cells, disrupts the PRMT5-RIOK1 complex, and reduces substrate methylation. BRD0639 is a first-in-class PBM-competitive small molecule that can support studies of PBM-dependent PRMT5 activities and the development of novel PRMT5 inhibitors that selectively target these functions.
Matching journals
The top 5 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Potent and Selective SETDB1 Covalent Negative Allosteric Modulator Reduces Methyltransferase Activity in Cells 97%
- Structure-guided bifunctional molecules hit a DEUBAD-lacking hRpn13 species upregulated in multiple myeloma 96%
- Enhancing Intracellular Accumulation and Target Engagement of PROTACs with Reversible Covalent Chemistry 96%
Similar papers in this journal
- Integrative x-ray structure and molecular modeling for the rationalization of procaspase-8 inhibitor potency and selectivity 95%
- Repurposing of the RIPK1 selective benzooxazepin-4-one scaffold for the development of a type-III LIMK1/2 inhibitor 95%
- Fragment-Based Development of NSP14 Exonuclease Inhibitors Confounded by Batch-to-Batch Variability 94%
Similar papers in this journal
Similar papers in this journal
Similar papers in this journal
- A direct high-throughput protein quantification strategy facilitates discovery and characterization of a celastrol-derived BRD4 degrader 96%
- An automatic pipeline for the design of irreversible derivatives identifies a potent SARS-CoV-2 Mpro inhibitor. 95%
- Tracking the PROTAC degradation pathway in living cells highlights the importance of ternary complex measurement for PROTAC optimization 95%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.